The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

Bortezomib is the first-in-class proteasome inhibitor, commonly used in the treatment of multiple myeloma (MM). The mechanisms underlying acquired bortezomib resistance in MM are poorly understood. Several cell-free miRNAs have been found to be aberrantly regulated in MM patients. The aim of this pi...

Full description

Bibliographic Details
Main Authors: Paweł Robak, Izabela Dróżdż, Dariusz Jarych, Damian Mikulski, Edyta Węgłowska, Monika Siemieniuk-Ryś, Małgorzata Misiewicz, Konrad Stawiski, Wojciech Fendler, Janusz Szemraj, Piotr Smolewski, Tadeusz Robak
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
bortezomib
efficacy
multiple myeloma
resistance
sensitivity
refractory
Online Access:https://www.mdpi.com/2072-6694/12/9/2569

Internet

https://www.mdpi.com/2072-6694/12/9/2569

Similar Items